AACR 2026 年会

Join us at #AACR26 for an update from FiREBOLT, a Phase 1 study investigating radioligand therapy for FAP expressing solid tumors.

We are getting ready for Day 2 of #AACR26, which will feature a full-day educational program, clinical trials minisymposia on Anticancer ...

AACR Project GENIE Will Show Off New Harmonization Data Model

Methods Workshop on the GENIE Data Model, an open-access framework for standardising clinical and genomic data across cancer centres. Chaired by Jeremy L. Warner (Brown University).

On day 2 of #AACR26 Dr. Stefania Morganti (

Ahead of

Cizzle Bio will attend the

With the

Expand your toolbox with all that CST has to offer, including InTraSeq™ Single Cell Analysis. Learn more at #AACR26, booth #3028!

#AACR26 君实生物公布 MSS 结直肠癌中的 PD‑1×VEGF 抗体 JS207（PD‑1 × VEGF 双特异性抗体）联合 XELOX 作为转移性 CRC 一线治疗的 II 期数据——而 IO 在该场景中历来未能奏效。 https:// aacrjournals.org/cancerres/arti cle/86/8_Supplement/CT152/783100/Abstract-CT152-Preliminary-results-from-a-phase-II?searchresult=1 … • 所有患者均为 MSS/pMMR CRC —

#AACR26 君实报告 PD‑1×VEGF + CTLA‑4 联合疗法用于 HCC JS207（PD‑1 × VEGF‑A 双特异性抗体）联合 JS007（抗 CTLA‑4）作为晚期肝细胞癌 1L 疗法的一项 II 期数据。 https:// aacrjournals.org/cancerres/arti cle/86/8_Supplement/CT159/782900/Abstract-CT159-JS207-a-bispecific-antibody?searchresult=1 … • 在这一难治性肿瘤中显示出较高的早期疗效信号：ORR

#AACR26 $MRK 将于 4 月 20 日通过口头报告公布 MK-2010 的临床数据。这是一种从 LaNova Medicines 收购的 PD-1/VEGF 双特异性抗体药物。所有数据均来自中国开展的临床试验。 摘要： https:// aacrjournals.org/cancerres/arti cle/86/8_Supplement/CT057/782906/Abstract-CT057-Preliminary-results-from-the-first?searchresult=1 … 来自一项的首次人体数据

Fascinating insights from #AACR26 on tackling resistance to KRasG12C-targeting drugs! Leveraging bystander mutations and exploring ration...

Day 1 highlights #AACR26: Approaches to overcome intrinsic or adaptive resistance to direct KRasG12C drugs: Leverage common bystander mut...

#AACR26 Daraxonrasib 单药疗法是一种 RAS(ON) 多选择性抑制剂，也正在崭露头角 在 1L mPDAC 中：ORR 47–51% DCR 92–97% 6 个月 PFS 71% 6 个月 OS 83% 对于胰腺癌的无化疗方案而言，这些结果令人振奋 https:// aacrjournals.org/cancerres/arti cle/86/8_Supplement/LB337/782959/Abstract-LB337-Daraxonrasib-monotherapy-as-first?searchresult=1 …

This evening, the 24 members of the 2026 class of AACR Fellows were inducted into the AACR Academy. The distinguished scientists who comp...

#AACR26 Wonders of HTAN

@IrenemGhobrial ⁩ 今天下午将在 #AACR26 介绍作为 NCI HTAN 计划一部分开展的部分 #myeloma 研究 #mmsm

Great session today at #AACR26 on NCI Human Tumor Atlas Network (HTAN).

Inflammatory breast cancer (IBC) at #AACR26 is not just aggressive—it’s a systems disease.

Great to connect with

Tonight, the 2026 class of Fellows will be inducted into the AACR Academy. We congratulate these newly-elected #AACRFellows, whose collec...

来自 @kevansf 的 #KRAS 抑制剂最新动态很有意思 再次聆听 Shokat 博士的分享太精彩了！此前，他曾在新年奥尔良举行的 AACR2022 上就 G12C 抑制剂作出一场开创性的演讲！ 未来方向：G12C+G12D/ 免疫调节/ Pr Vaccine @AACR #AACR26

After her education session at #AACR26, we caught up with Jessica Islam, PhD (

Focus on hematologic malignancies at #AACR26, with the latest in scientific advances and clinical innovations. Explore the full schedule ...

The Dark Side of Cancer Therapies - And Potential Solutions

Sheila A. Stewart (Washington University in St. Louis) on chemotherapy-induced peripheral neuropathy: about 70% of patients on chemotherapy experience it, and 20-30% have symptoms that last their whole lives.

Policy meets practice at #AACR26, with two session tracks examining how evolving regulations impact researchers, clinicians, patients, an...

Is the live stream cutting out due to an issue on my end? #AACR26

#AACR26 通过联合用药提高 #KRAS 抑制剂的疗效 Ambrogio 博士 @unito KRASi 上游和下游 KRASi 与其他通路抑制剂 #ALK 联合使用 同时开启和关闭 KRASi #KRAS 领域是 @OncoAlert

#AACR26

DCR is a time-varying function of an unspecified estimand, reported as a scalar, at an investigator-selected landmark, under informative ...